89BIO INC. - COMMON STOCK

89bio to Participate in the Leerink Partners Global Healthcare Conference

03 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

27 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

03 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

28 Jan 2025 21:31:17 By Nasdaq GlobeNewswire

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

27 Jan 2025 15:12:25 By Nasdaq GlobeNewswire

89bio Provides Business Update and Outlook for 2025

13 Jan 2025 07:00:01 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Nov 2024 12:30:00 By Nasdaq GlobeNewswire

89bio to Participate in the 7th Annual Evercore HealthCONx Conference

26 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

15 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

12 Nov 2024 22:58:01 By Nasdaq GlobeNewswire

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

12 Nov 2024 15:01:31 By Nasdaq GlobeNewswire

89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

07 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Participate in the UBS Global Healthcare Conference

05 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

15 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

30 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 Sep 2024 15:03:00 By Nasdaq GlobeNewswire

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

16 Sep 2024 15:05:00 By Nasdaq GlobeNewswire